China said it has administered more than 1 million coronovirus vaccines since July and plans to distribute more, initially targeting workers in industries where they are at high risk of infection because The country wants to work on the global Kovid-19 vaccination front. Effort.
Vaccines developed by Synovac Biotech Limited and state-owned China National Biotech Group Company, known as CNBG, Disseminated in the country since the Emergency Use Authority was granted in July.
China is now planning a wider distribution of experimental shots with people working in hospitals, customs, public transport and cold-chain logistics, as well as vulnerable groups including those with pre-acquired medical conditions. for. The general public will be involved in the later phase of the rollout, China’s National Health Commission vice-chairman Zeng Yixin told reporters in Beijing on Saturday.
Zeng said that the cold weather with the onset of winter poses challenges to the control of China’s virus, which has ended internally with a combination of strict border control and mass testing.
“Our goal is to establish herd immunity through vaccination so that Kovid-19 can be rapidly controlled effectively,” he said.
This vaccine is applied to China Ahead of the US and UK, which recently granted emergency authorization to shots developed by pharmaceutical giant Pfizer Inc. and Germany’s Biotech SE, allowing them to begin vaccinating people in specific target groups. America Also cleaned a Kovid-19 vaccine from Modern Inc. on Friday. According to data compiled by Bloomberg, Russia, which says it is already delivering door-to-door shots to its population, has vaccinated 320,000 people.
The figure of 1 million refers to the administered dose, not the number of vaccines. CNBG President Yang Xiaoming recently said that according to the local, more than 650,000 people were administered Chinese vaccines Media reports. Both CNBG and Synovac candidates follow a two-shot regiment of an initial jab and then a booster.
Follow the global vaccine rollout here with BloombergIs the tracker
Although Chinese officials did not say how many people would be vaccinated in the next stages of the vaccination effort, Bloomberg reported on Friday that officials plan to manage locally-developed shots. More than 50 million workers were exposed to the virus in early February, a significant expansion that would mobilize local branches, medical clinics and hospitals at China’s Center for Disease Control and Prevention to meet the ambitious goal.
The rollout, which comes amid speculation that China is close to signing drug regulators CNBG and Synovac vaccines for general use, would be equivalent to vaccinating the entire population of South Korea in less than two months, a move. Which will put. The country stands out well in the race for distribution if it succeeds. The rapid deployment of coronovirus testing in China over the past few months, after millions of days of testing after cases were identified, could be a model for how the country of 1.4 billion people wants to be approached for vaccination.
The plan to vaccinate 50 million people underscores Beijing’s focus on preventing a repeat of the deadly outbreak that began in Wuhan city earlier this year. Although China has virtually sealed the local transmission of the virus and life has largely returned to normal for the majority of its population, in recent weeks there has been a spate of infections in the country’s northeastern province of Heilongjiang, west of Xinjiang and Sichuan. The blueprint has been revealed. , And even in the highly protected Chinese capital.
Zheng Zhongwei, a director who oversees coronovirus vaccine development at the National Health Commission on Saturday, has not seen any serious side effects among those receiving Chinese vaccines. China will disclose data “on time” on the efficacy of Chinese shots, with developers filing an update to the drug regulator on a rolling basis.
Compared to Western vaccine efforts, Very few data on efficacy and safety have been made public by late human trials on Chinese shots. Five candidates for the vaccine are in the final stages, with phase III clinical trials being carried out in virus hotspots in Southeast Asia, South America and the Middle East.
Transparency and the relative lack of information have cast doubt on China’s shots, which President Xi Jinping said will be rolled out globally. The country is also part of the World Health Organization Kovacs initiative designed to distribute vaccines to developing countries.
Chinese vaccine developers have also included supply deals with countries such as Indonesia, Singapore, Turkey and the United Arab Emirates, which said earlier this month that CNBG’s shot into a local clinical trial of more than 30,000 people An efficacy rate of 86% was shown.
Research indicates that China’s vaccines bear the cost of protection against Kovid-19 for at least six months, Zeng of the National Health Commission said in Saturday’s briefing. Antibodies continue to be detected in people receiving shots in early March, he said.
Approach to rescue
With the massive immunization effort shifting to gear, China’s CDC will take advantage of its existing surveillance systems to keep track of any serious side effects from Kovid-19 vaccines, the body’s chief immunization expert Wang Huang said. China’s mechanisms for monitoring vaccine safety meet WHO’s standards and have the ability to identify and treat any side effects that hospitals and clinics will manage shots nationwide, he said.
Officers have It has previously been said that no such serious adverse events have occurred – those who receive the vaccine may sometimes stop clinical trials – in those vaccinated under the Emergency Use Program. The country has defended its broader interpretation of the Emergency Authority, which includes activists from state-owned companies located abroad, stating that Kovid-19 is at greater risk of returning through its borders.
– Assisted by Emma O’Brien, Claire Che and Dong Luu
(Updates with the executive on the number of vaccinations in the seventh paragraph.)